Cytogenetic and dosimetric effects of 131I in patients with differentiated thyroid carcinoma: comparison between stimulation with rhTSH and thyroid hormone withdrawal treatments

[1]  A. Amaral,et al.  Biological dose assessment after low-dose overexposures in nuclear medicine. , 2014, Radiation protection dosimetry.

[2]  M. R. Carvalho,et al.  Evaluation of whole-body retention of iodine-131 ((131)I) after postoperative remnant ablation for differentiated thyroid carcinoma - thyroxine withdrawal versus rhTSH administration: A retrospective comparison. , 2012, Oncology letters.

[3]  Markus Luster,et al.  Dosimetry and thyroid cancer: the individual dosage of radioiodine. , 2010, Endocrine-related cancer.

[4]  P. Auquier,et al.  Iodine biokinetics and radioiodine exposure after recombinant human thyrotropin-assisted remnant ablation in comparison with thyroid hormone withdrawal. , 2010, The Journal of clinical endocrinology and metabolism.

[5]  R. Kloos,et al.  Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma. , 2009, Endocrine-related cancer.

[6]  M. Davi’,et al.  Chromosome translocation frequency after radioiodine thyroid remnant ablation: a comparison between recombinant human thyrotropin stimulation and prolonged levothyroxine withdrawal. , 2009, The Journal of clinical endocrinology and metabolism.

[7]  Amy Y. Chen,et al.  Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005 , 2009, Cancer.

[8]  F. Pacini,et al.  Diagnostic and therapeutic use of recombinant human TSH (rhTSH) in differentiated thyroid cancer. , 2008, Best practice & research. Clinical endocrinology & metabolism.

[9]  S. Purisch,et al.  Preparation with Recombinant Human Thyroid-Stimulating Hormone for Thyroid Remnant Ablation with 131I Is Associated with Lowered Radiotoxicity , 2008, Journal of Nuclear Medicine.

[10]  M. Schlumberger,et al.  131I Effective Half-Life and Dosimetry in Thyroid Cancer Patients , 2008, Journal of Nuclear Medicine.

[11]  C. Buchpiguel,et al.  Evaluation of the cytogenetic effects of 131I preceded by recombinant human thyrotropin (rhTSH) in peripheral lymphocytes of Wistar rats , 2008, Radiation and environmental biophysics.

[12]  M. Luster,et al.  EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  M. Schlumberger,et al.  Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients: comparison between preparation with thyroid hormone withdrawal and thyrogen , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  S. Hall,et al.  Increased incidence of differentiated thyroid carcinoma and detection of subclinical disease , 2007, Canadian Medical Association Journal.

[15]  V. Vicente,et al.  Biological dosimetry and Bayesian analysis of chromosomal damage in thyroid cancer patients. , 2007, Radiation protection dosimetry.

[16]  Markus Luster,et al.  Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  M. Luster.  Present status of the use of recombinant human TSH in thyroid cancer management , 2006, Acta oncologica.

[18]  M. Luster,et al.  rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. , 2005, Endocrine-related cancer.

[19]  M. Ribela,et al.  Two-step chromatographic purification of recombinant human thyrotrophin and its immunological, biological, physico-chemical and mass spectral characterization. , 2005, Journal of chromatography. A.

[20]  Anne Hoekstra,et al.  Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  H. Kanegane,et al.  The radiotoxicity of 131I therapy of thyroid cancer: assessment by micronucleus assay of B lymphocytes. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  Semra Ozdemir,et al.  Iodine-131 treatment and chromosomal damage: in vivo dose-effect relationship , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[23]  B. Shulkin,et al.  Increasing efficacy and safety of treatments of patients with well-differentiated thyroid carcinoma by measuring body retentions of 131I. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  L. Migliore,et al.  Formation of micronuclei and of clastogenic factor(s) in patients receiving therapeutic doses of iodine-131. , 2002, Mutation research.

[25]  L. Feinendegen,et al.  Biologic responses to low doses of ionizing radiation: Detriment versus hormesis. Part 2. Dose responses of organisms. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  C. Catena,et al.  Micronucleus yield and colorimetric test as indicators of damage in patients' lymphocytes after 131I therapy. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  R. Marcos,et al.  Cytogenetic damage after 131-iodine treatment for hyperthyroidism and thyroid cancer , 1999, European Journal of Nuclear Medicine.

[28]  H. Thierens,et al.  Estimation of risk based on biological dosimetry for patients treated with radioiodine. , 1999, Nuclear medicine communications.

[29]  R. Marcos,et al.  The alkaline single-cell gel electrophoresis (SCGE) assay applied to the analysis of radiation-induced DNA damage in thyroid cancer patients treated with 131I. , 1998, Mutation research.

[30]  N. Shuke,et al.  Radiotoxicity after iodine-131 therapy for thyroid cancer using the micronucleus assay. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[31]  R. Marcos,et al.  Radioactive iodine induces clastogenic and age-dependent aneugenic effects in lymphocytes of thyroid cancer patients as revealed by interphase FISH. , 1997, Mutagenesis.

[32]  P. Zanzonico,et al.  Radiation dose to patients and relatives incident to 131I therapy. , 1997, Thyroid : official journal of the American Thyroid Association.

[33]  M. Schlumberger,et al.  Sequential biological dosimetry after a single treatment with iodine-131 for differentiated thyroid carcinoma. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[34]  M. Schlumberger,et al.  Biological dosimetry in patients treated with iodine-131 for differentiated thyroid carcinoma. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[35]  M. Füzy,et al.  Cytogenetic study of radiation burden in thyroid disease patients treated with external irradiation or radioiodine. , 1996, Mutation research.

[36]  M. Lemaire,et al.  Chromosome aberrations after treatment with radioactive iodine for thyroid cancer. , 1994, Radiation research.

[37]  B. Weintraub,et al.  Recombinant Human Thyroid Stimulating Hormone: Development of a Biotechnology Product for Detection of Metastatic Lesions of Thyroid Carcinoma , 1993, Bio/Technology.

[38]  M. Luster,et al.  Recombinant human thyrotropin: safety and quality of life evaluation. , 2012, Journal of endocrinological investigation.

[39]  E. Hindié,et al.  Overview on the use of recombinant human thyrotropin in thyroid cancer of follicular cell origin. , 2008, Minerva endocrinologica.

[40]  O. Monteiro Gil,et al.  Cytogenetic alterations and oxidative stress in thyroid cancer patients after iodine-131 therapy. , 2000, Mutagenesis.

[41]  J. F. Briesmeister.  MCNP-A General Monte Carlo N-Particle Transport Code , 1993 .